Vol. 22/No. 23 | OncologyLive

Nectin-4 Emerges as a Therapeutic Target in Urothelial Carcinoma and Beyond

January 02, 2022

Most ongoing clinical trials exploring nectin-4 as a target involve studies of enfortumab vedotin and its potential synergy with immune checkpoint inhibitors in bladder cancer, while several other early-phase studies are testing novel agents in solid tumors.

Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade

December 30, 2021

The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.

Novel Agents Shake Up Myelodysplastic Syndrome Treatment Landscape

December 27, 2021

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts shared their insights on the most recent FDA-approved agents for MDS, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020.

It Is Time to Reexamine Control Arms in Phase 3 Trials

December 23, 2021

Maurie Markman, MD on strategies to appropriately evaluate small but clinically relevant patient subsets for whom traditional phase 3 randomized clinical trials are difficult, if not impossible, to complete in a realistically timely manner.